Phentolamine mesylate

• CAT Number: I004463
• CAS Number: 65-28-1
• Molecular Formula: C17H19N3O • CH3SO3H
• Molecular Weight: 377.5
• Purity: ≥95%
• Target: Adrenergic Receptor
• Solubility: DMSO 75 mg/mL; Water 75 mg/mL
• Storage: 3 years -20C powder
• IUPAC Name: 3-[N-(4,5-dihydro-1H-imidazol-2-ylmethyl)-4-methylanilino]phenol;methanesulfonic acid
• InChI: InChI=1S/C17H19N3O.CH4O3S/c1-13-5-7-14(8-6-13)20(12-17-18-9-10-19-17)15-3-2-4-16(21)11-15;1-5(2,3)4/h2-8,11,21H,9-10,12H2,1H3,(H,18,19);1H3,(H,2,3,4)
• InChIKey: OGIYDFVHFQEFKQ-UHFFFAOYSA-N
• SMILES: CC1=CC=C(C=C1)N(CC2=NCCN2)C3=CC(=CC=C3)O.CS(=O)(=O)O

Phentolamine mesylate(CAT: I004463) is a nonselective alpha-adrenergic antagonist. It works by blocking the alpha-adrenergic receptors, which are responsible for the constriction of blood vessels. By blocking these receptors, phentolamine mesylate causes relaxation of the smooth muscles in blood vessel walls, leading to vasodilation and increased blood flow. It is primarily used in the management of conditions such as hypertension, pheochromocytoma (a tumor of the adrenal gland), and certain types of erectile dysfunction.

Overview of Clinical Research

Phentolamine Mesylate is an alpha adrenergic receptor antagonist developed by Novalar Pharmaceuticals.

Reference

1:Phase Four, Randomized, Double-Blinded, Controlled Trial of Phentolamine Mesylate in Two- to Five-year-old Dental Patients. Hersh EV, Lindemeyer R, Berg JH, Casamassimo PS, Chin J, Marberger A, Lin BP, Hutcheson MC, Moore PA, Group PS.Pediatr Dent. 2017 Jan 15;39(1):39-45. PMID: 28292340
2:Effectiveness and safety of phentolamine mesylate in routine dental care. Daubländer M, Liebaug F, Niedeggen G, Theobald K, Kürzinger ML.J Am Dent Assoc. 2017 Mar;148(3):149-156. doi: 10.1016/j.adaj.2016.11.017. Epub 2017 Jan 23. PMID: 28126226
3:Phentolamine mesylate to reverse oral soft-tissue local anesthesia: A systematic review and meta-analysis. Prados-Frutos JC, Rojo R, González-Serrano J, González-Serrano C, Sammartino G, Martínez-González JM, Sánchez-Monescillo A.J Am Dent Assoc. 2015 Oct;146(10):751-9.e3. doi: 10.1016/j.adaj.2015.04.018. Review. PMID: 26409985
4:Phentolamine mesylate: It/'s role as a reversal agent for unwarranted prolonged local analgesia. Grover HS, Gupta A, Saksena N, Saini N.J Indian Soc Pedod Prev Dent. 2015 Oct-Dec;33(4):265-8. doi: 10.4103/0970-4388.165646. Review. PMID: 26381625 Free Article
5:Evaluating complications of local anesthesia administration and reversal with phentolamine mesylate in a portable pediatric dental clinic. Boynes SG, Riley AE, Milbee S, Bastin MR, Price ME, Ladson A.Gen Dent. 2013 Aug;61(5):70-6. PMID: 23928444
6:Effect of phentolamine mesylate on duration of soft tissue local anesthesia in children. Nourbakhsh N, Shirani F, Babaei M.J Res Pharm Pract. 2012 Oct;1(2):55-9. doi: 10.4103/2279-042X.108371. PMID: 24991590 Free PMC Article
7:What/'s new with phentolamine mesylate: a reversal agent for local anaesthesia? Yagiela JA.SAAD Dig. 2011 Jan;27:3-7. Review. PMID: 21323030
8:The use of phentolamine mesylate to evaluate mandibular nerve damage following implant placement. Froum SJ, Froum SH, Malamed SF.Compend Contin Educ Dent. 2010 Sep;31(7):520, 522-8. PMID: 20879205
9:Phentolamine mesylate for accelerating recovery from lip and tongue anesthesia. Hersh EV, Lindemeyer RG.Dent Clin North Am. 2010 Oct;54(4):631-42. doi: 10.1016/j.cden.2010.06.004. Review. PMID: 20831927
10:Local and systemic toxicity of intraoral submucosal injections of phentolamine mesylate (OraVerse). Rutherford B, Zeller JR, Thake D.Anesth Prog. 2009 Winter;56(4):123-7. doi: 10.2344/0003-3006-56.4.123. PMID: 20020792 Free PMC Article